CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option

FDA DecisionLirafugratiniblirafugratinib
Related Companies

Read the original article

Published by GlobeNewswire Pharma on September 23, 2026 9:54 PM

Read Original